DelveInsight’s ‘Prostate Cancer- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Prostate Cancer Understanding
Prostate cancer a type of malignancy that occurs in the prostate gland. The prostate is a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate cancer is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. According to the Cancer Treatment Centers of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. It is common in men of 50–64 years and over age 65; however, it can occur in men younger than 50 years. Symptoms of adenocarcinoma of the prostate include blood in the semen, frequent urge to urinate, and painful urination and ejaculation. The symptoms of prostate cancer do not usually appear until the prostate is large enough to affect the tube that carries urine from the bladder out of the penis.
Many patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE), prostate ultrasound, prostate MRI, prostate Mp-MRI. Screening is a type of testing to find cancer in people before they have symptoms. It is not clear, however, if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. If the result of one of these tests is abnormal, patients will probably need a prostate biopsy to know for sure the occurrence of cancer. Clinical Stage and treatment pattern are key factors in Prostate Cancer.
“In clinical-stage-wise cases of prostate cancer, most of the cases were of the localized stage, which accounted for approximately 60% of the total diagnosed prevalent cases in 2017. On the other hand, metastatic cases accounted for only 7% of the total diagnosed prevalent cases.”
Patients who have never received, i.e., are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). Further down the line, many prostate cancers patients ultimately fail to respond to ADT and are termed castrate-resistant prostate cancer (CRPC).
“It was accessed that around 78% of biochemical recurrence/ progressive cases are non-metastatic castrate sensitive prostate cancer (nmCSPC/ nmHSPC).”
Epidemiology Perspective by DelveInsight
The Prostate Cancer epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The Prostate Cancer epidemiology data are studied through Prostate Cancer possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted Prostate Cancerepidemiology [segmented as Total Prevalent Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer, Age-specific Cases of Prostate Cancer, Total Diagnosed cases of Prostate Cancer patients by Clinical Stages, Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC, Total Treated cases of Non-metastatic CSPC/HSPC and CRPC, Total Treated Cases of mHSPC/CSPC] scenario of Prostate Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.
Prostate Cancer Detailed Epidemiology Segmentation
• The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 cases in 2017, and are expected to increase during the study period.
• Estimates show the highest diagnosed population of Prostate Cancer is in the United States. in EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 360,916 cases in 2017, followed by France and Italy.
• Our estimation suggested that the total treated patient pool of mCSPC/HSPC was 75,600 in 2017, will likely increase throughout the study period, besides nearly 73,452 cases of mCRPC treated in first-line.
• According to the DelveInsight, in 2017, total treated pool nmCRPC progressed from first-line to the second-line was found to be 160,287. On the other hand, the total treated patient pool of nmCSPC/HSPC was 668,577 cases in the 7MM (2017).
Scope of the Report
• The Prostate Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Prostate Cancer Report and Model provide an overview of the risk factors and global trends of Prostate Cancer in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of Prostate Cancer in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Prostate Cancer.
• The report provides the segmentation of the Prostate Cancer epidemiology by total prevalent cases of Prostate Cancer in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by total diagnosed prevalent cases of Prostate Cancer in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by total diagnosed cases of Prostate Cancer patients by clinical stages in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Age-specific Cases in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Treated cases of Non-metastatic CSPC/HSPC and CRPC in the 7MM.
• The report provides the segmentation of the Prostate Cancer epidemiology by Treated Cases of mHSPC/CSPC in the 7MM.
• 11-Year Forecast of Prostate Cancer epidemiology
• 7MM Coverage
• Total Prevalent Cases of Prostate Cancer
• Total Diagnosed Cases of Prostate Cancer
• Age-specific Cases of Prostate Cancer
• Total Diagnosed cases of Prostate Cancer patients by Clinical Stages
• Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC
• Total Treated cases of Non-metastatic CSPC/HSPC and CRPC
• Total Treated Cases of mHSPC/CSPC
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Prostate Cancer scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Prostate Cancer?
• What are the key findings pertaining to the Prostate Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Prostate Cancer across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Prostate Cancer?
Reasons to buy
The Prostate Cancer Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Prostate Cancer market
• Quantify patient populations in the global Prostate Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Prostate Cancer therapeutics in each of the markets covered
• Understand the magnitude of Prostate Cancer population by its severity
• The Prostate Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Prostate Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Prostate cancer is most frequently diagnosed among men aged 65–74 years, median age at diagnosis is 66 years. According to DelveInsight’s analysts the total number of age-specific cases in the United States for the age-group 65–74 years, was found to be 500,926, in 2017
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook